Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis-Reference-Cited by-同舟云学术

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis

Published:2021-01-15 Issue:2 Volume:64 Page:1127-1138
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Milliken Brandon T.¹,Elfers Clinton²,Chepurny Oleg G.³,Chichura Kylie S.¹,Sweet Ian R.⁴,Borner Tito⁵,Hayes Matthew R.⁶,De Jonghe Bart C.⁵,Holz George G.³,Roth Christian L.²,Doyle Robert P.¹³^ORCID

Affiliation:

1. Department of Chemistry, Syracuse University, 111 College Place, Syracuse, New York 13244, United States

2. Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, Washington 98105, United States

3. Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York 13210, United States

4. Diabetes Research Institute, University of Washington, Seattle, Washington 98105, United States

5. Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

6. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Funder

Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung

National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Defense

Syracuse University

Center for Integrative Brain Research, Seattle Children's Hospital

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01783

Reference77 articles.

1. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults

2. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

3. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

4. GLP-1 and weight loss: unraveling the diverse neural circuitry

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of incretin receptor agonists in the treatment of obesity;Diabetes, Obesity and Metabolism;2024-07-29

2. The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner;Frontiers in Endocrinology;2024-07-22

3. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist;Clinical Nutrition;2024-07

4. Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis;Neuropeptides;2024-06

5. The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner;2024-05-21